man, that's grand, especially the last paragraph. I definitely should be less modest with my resume :)
"Stat reported that in 2017, Richard Graydon self-published a book titled The Genetic Risks of Cancer: The Effects of DNA, Genomics and Inheritance on Aging and Survival.” The book described Graydon as an oncologist who had served as a chief medical officer in the biotech and drug development industry. It had no reviews on Amazon.
In October 2022, Atossa Therapeutics, a Seattle-based biotech, announced it had hired Richard Graydon as its interim chief medical officer.
“We are privileged to welcome Richard to Atossa, where his deep experience in CAR-T cell therapy fits well with our current strategic direction as we explore our opportunities in cell therapy,” Steven Quay, Atossa’s CEO, said in a statement at the time.
In March, Immix announced hiring Graydon, calling him a “board-certified hematologist-oncologist with over 20 years of experience in clinical development, most recently at Merck & Co. and Johnson & Johnson, where he led new and supplemental new drug applications and biologics license applications for 7 approved drugs including Darzalex, Carvykti, Keytruda, and Imbruvica.” Stat noted that these are some of the bestselling cancer medicines in the world."
